Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis.
about
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine modelTMC207: the first compound of a new class of potent anti-tuberculosis drugsEmerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?Current prospects for the fluoroquinolones as first-line tuberculosis therapyAntituberculosis therapy for 2012 and beyondTuberculosis, nontuberculous lung infection, pleural disorders, pulmonary function, respiratory muscles, occupational lung disease, pulmonary infections, and social issues in AJRCCM in 2004Prospects for advancing tuberculosis control efforts through novel therapiesBuilding clinical trials capacity for tuberculosis drugs in high-burden countriesSterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosisAutoluminescent Mycobacterium tuberculosis for rapid, real-time, non-invasive assessment of drug and vaccine efficacyCharacterization of a novel cell wall-anchored protein with carboxylesterase activity required for virulence in Mycobacterium tuberculosisTuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primatesInsights into the pharmacokinetic properties of antitubercular drugs.Challenges in the clinical assessment of novel tuberculosis drugs.Recent advances in tuberculosis: New drugs and treatment regimens.Pharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment durationRifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.Current Status of Fluoroquinolone Use for Treatment of Tuberculosis in a Tertiary Care Hospital in KoreaBactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis.Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trialEfficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis.Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.Four-month moxifloxacin-based regimens for drug-sensitive tuberculosisCombinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosisSynergistic activity of R207910 combined with pyrazinamide against murine tuberculosisNew regimens for reducing the duration of the treatment of drug-susceptible pulmonary tuberculosis.Current development and future prospects in chemotherapy of tuberculosisA sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosetsPotent twice-weekly rifapentine-containing regimens in murine tuberculosis.A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary TuberculosisSterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis.Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosisMetronidazole validates drugs targeting hypoxic bacteria for improved treatment of tuberculosisEfficacy of moxifloxacin & econazole against multidrug resistant (MDR) Mycobacterium tuberculosis in murine model.Update in tuberculosis 2005.Confronting the scientific obstacles to global control of tuberculosis.Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.
P2860
Q21144660-5DCF4A14-B7AF-42D7-8302-C43EDB4ABB87Q24632091-85A3207E-22E2-4E81-BEC8-0EA40BC2F52DQ26771997-09684D2D-0739-4D1D-B446-861207CE93A7Q26823843-35C7696E-718D-4F88-9E7B-79E680D38829Q26829101-FB8899ED-6637-4B60-8ECB-4A811F733F3CQ28238675-116874F6-2B66-4198-A132-F5165E26E663Q28469031-A600B20C-6186-430E-B694-02B24B567611Q28469348-3088063F-6ACE-4645-8727-5105A2881D8FQ28477317-58133145-9683-44ED-8034-1B4024850FD7Q28478840-CDF6F790-9D60-406F-88C5-9358B311E0ADQ28486765-23138950-29E8-484C-9DB8-6C3B6A229EDDQ29618010-81380252-6D35-470D-B597-DF78A1754B6FQ30251497-6345B6BA-5DF1-4396-A55F-5CB485FB02A2Q30251933-CA233E7B-6C26-4620-8648-062B1DBD261EQ30360811-4DE097B0-5F14-44BA-AD02-FA9129EA246EQ30377051-94108F4A-DF16-4C79-A6E8-FC96154849D0Q30834393-5C0E67DA-42FB-4779-A2B9-0C1AC3C49B1DQ33567352-288DB209-364E-4E80-8924-4C994D80DC48Q33836692-3FA76955-DCC9-4607-8F80-B2F3BE306C8FQ33837706-668C0595-0A0C-4C2C-9C37-685F5935487DQ34077125-D3D25246-6C82-4598-89AE-46060D963DD1Q34290060-F0F933F8-0B82-4DEC-A74E-210A81A3F742Q34737143-57E17230-612A-4C40-8E7E-5B7F419E25C8Q34777926-9B81C768-BC56-4960-A34B-0F21D82A97CDQ35127770-D8770316-66F4-46F8-9AC4-5E50268D8E25Q35598474-D61B3951-BC81-4F4A-A689-18B572FCBC68Q35647811-26A202BF-590B-4069-94E2-A71B9F5323F9Q35676180-8DE471F8-6338-4115-A1F6-774D0DBDA201Q35705874-7524227B-79EC-4BB9-8C11-083BA9CF2CB6Q35745991-06AAE78B-70A4-47AC-BE3A-1610B1EB336BQ35776635-1E0AD2C0-1B33-4D80-A12B-B5F802BA260DQ36012300-7330AEBC-99C3-47E8-A39D-7144CDC34E00Q36018542-37FB75EB-AF64-4863-83D0-DC9C44E522AAQ36018624-1312B89E-4EF7-4678-B3F7-C917AC88C846Q36171524-A7B3D227-EE2F-4691-9E92-06956D96056BQ36212780-BEE8F78F-0AE2-4674-ABBF-7EDEE30F944FQ36347436-BBB499E0-6F31-4950-A6B6-1146EAB3CD40Q36403165-169D8419-6569-4C10-8A02-3EDC944B5F41Q36513366-45772B0D-1B73-4775-BC25-34620E879DBFQ36538719-4E9E6DB3-CC97-425B-8870-4F09501F28BF
P2860
Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis.
description
2004 nî lūn-bûn
@nan
2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
name
Moxifloxacin-containing regime ...... e cure in murine tuberculosis.
@ast
Moxifloxacin-containing regime ...... e cure in murine tuberculosis.
@en
Moxifloxacin-containing regime ...... e cure in murine tuberculosis.
@nl
type
label
Moxifloxacin-containing regime ...... e cure in murine tuberculosis.
@ast
Moxifloxacin-containing regime ...... e cure in murine tuberculosis.
@en
Moxifloxacin-containing regime ...... e cure in murine tuberculosis.
@nl
prefLabel
Moxifloxacin-containing regime ...... e cure in murine tuberculosis.
@ast
Moxifloxacin-containing regime ...... e cure in murine tuberculosis.
@en
Moxifloxacin-containing regime ...... e cure in murine tuberculosis.
@nl
P2093
P2860
P1476
Moxifloxacin-containing regime ...... e cure in murine tuberculosis.
@en
P2093
Andrew A Vernon
Eric L Nuermberger
Ian Rosenthal
Jacques H Grosset
Kathy Williams
Richard J O'Brien
Sandeep Tyagi
Tetsuyuki Yoshimatsu
William R Bishai
P2860
P304
P356
10.1164/RCCM.200407-885OC
P407
P577
2004-08-11T00:00:00Z